Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients with Cirrhosis and Acute Decompensation

Hepatology

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Lancet.

Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J

Hepatology

Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis

doi: 10.1038/s41395-018-0421-0.

Hepatology

Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis

Gastroenterology.

Intagliata NM, Caldwell SH, Tripodi A

doi: 10.1053/j.gastro.

Hepatology

Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

BMC Gastroenterol.

Hayashi T, Takatori H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Shimakami T, Arai K, Kitamura K, Kawaguchi K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Toyama T, Okumura K, Kozaka K, Kaneko S

doi: 10.1186/s12876-019-1140-8.

Hepatitis

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

J Hepatol.

Lens S, Baiges A, Alvarado E, LLop E, Martinez J, Fortea JI, Ibañez L, Mariño Z, Rodríguez-Tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, García-Pagán JC, Forns X

doi: 10.1016/j.jhep.2020.05.050.

Hepatology

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

J Hepatol.

López-Vicario C, Checa A, Urdangarin A, Aguilar F, Alcaraz-Quiles J, Caraceni P, Amorós A, Pavesi M, Gómez-Cabrero D, Trebicka J, Oettl K, Moreau R, Planell N, Arroyo V, Wheelock CE, Clària J

doi: 10.1016/j.jhep.2020.03.046.

Hepatology

Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation

J Gastroenterol Hepatol.

Grønbaek H, Møller HJ, Saliba F, Zeuzem S, Albillos A, Ariza X, Graupera I, Solà E, Amoros A, Pavesi M, Bossen L, Jalan R, Gines P, Arroyo V, CANONIC investigators, EASL CLIF Consortium.

doi: 10.1111/jgh.15125.

Hepatology

PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

J Hepatol

Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia-Lopez E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Praktiknjo M, Curto A, Pitarch C, Putignano A, Moreno E, Bernal W, Aguilar F, Clària J, Ponzo P, Vitalis Z, Zaccherini G, Balogh B, Gerbes A, Vargas V, Alessandria C, Bernardi M, Ginès P, Moreau R, Angeli P, Jalan R, Arroyo V, PREDICT STUDY group of the EASL-CLIF CONSORTIUM.

doi: 10.1016/j.jhep.2020.11.019

Inflammatory Bowel Disease

Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis

Dig Dis Sci.

Nevens F, Bittencourt PL, Coenraad MJ, Ding H, Hou MC, Laterre PF, Mendizabal M, Ortiz-Olvera NX, Vorobioff JD, Zhang W, Angeli P

doi: 10.1007/s10620-018-5448-y.

Related content

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis

Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis

Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation

PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis